Hepatitis C News and Research

Latest Hepatitis C News and Research

EB Pharma licenses tipifarnib from Janssen to study potential new therapy for HDV

EB Pharma, LLC., a subsidiary of Eiger BioPharmaceuticals, Inc., announced that it has executed an agreement with Janssen Pharmaceutica NV, for an exclusive license, to tipifarnib in the field of virology and a related, clinical stage back-up compound.

23 Dec 2014

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

AbbVie receives Health Canada approval for HOLKIRA PAK (ombitasvir/paritaprevir/ritonavir film-coated tablets; dasabuvir film-coated tablets), an all-oral, short-course (12 weeks for the majority of patients), interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with cirrhosis.

23 Dec 2014

Study underscores the importance of appropriate testing, support and care for HCV patients

A new study shows that many patients infected with the hepatitis C virus (HCV) are lost during different stages of health care to manage the disease.

23 Dec 2014

Medical researchers at Saint Louis University bring hope to those in pain and sickness

This year, Saint Louis University medical researchers advanced their fields, contributing to human knowledge and bringing hope to those in pain and sickness.

23 Dec 2014

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

The U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis.

21 Dec 2014

New analysis finds global improvements in life expectancy

Global life expectancy increased by 5.8 years in men and 6.6 years in women between 1990 and 2013, according to a major new analysis from the Global Burden of Disease Study 2013 (GBD 2013).

19 Dec 2014

LSDF announces $1.2 million in grants to foster advancement of promising health-related technologies

The Life Sciences Discovery Fund today announced $1.2 million in Proof of Concept grants to Washington-based organizations to foster the advancement of promising health-related technologies to commercial products. Also announced were two commercialization-focused awards, totaling $600,000, through a new funding program requiring external cash matching.

18 Dec 2014

New study highlights importance of generating awareness about HCV testing, support and care

A new study shows that many patients infected with the hepatitis C virus (HCV) are lost during different stages of health care to manage the disease. This real-life' view of the HCV patient care continuum in a major U.S. urban area is published in Hepatology, a journal of the American Association for the Study of Liver Diseases, and highlights the importance of generating awareness among clinicians and at-risk groups about appropriate HCV testing, referral, support and care.

18 Dec 2014

HEPscreen Toolkit seeks to raise awareness on chronic viral hepatitis in Europe

A new toolkit on screening for chronic viral hepatitis seeks to raise awareness, improve knowledge and motivate public health professionals in Europe to take action. Knowledge and understanding of what works in screening for chronic hepatitis B/C has now been translated into practical and relevant tools, including videos and animations, to enable others to replicate successful screening programmes among at risk populations in their area.

14 Dec 2014

New study eliminates hepatitis C virus as causative factor of mental impairment in HIV patients

Advances in treatment for human immunodeficiency virus (HIV) have made it possible for people with HIV to survive much longer. As they age, however, many experience impaired thinking, memory loss, mood swings and other evidence of impaired mental function.

14 Dec 2014

New study helps identify public health needs relating to HIV/AIDS, hepatitis C in Massachusetts

A new study from epidemiologists at Tufts University School of Medicine helps to identify communities with the greatest public health need in Massachusetts for resources relating to HIV/AIDS and hepatitis C.

14 Dec 2014

Two MinuteClinic walk-in medical clinics open inside CVS/pharmacy stores in Northern Nevada

Two MinuteClinic walk-in medical clinics opened today inside CVS/pharmacy stores in Reno and Sparks. They join eight MinuteClinic locations inside select CVS/pharmacy stores in the Las Vegas area in Southern Nevada.

14 Dec 2014

Smaller blood transfusions during surgeries better for patients with heart disease

Patients with heart disease who receive transfusions during surgeries do just as well with smaller amounts of blood and face no greater risk of dying from other diseases than patients who received more blood, according to a new Rutgers study.

11 Dec 2014

Potential new active substances for treating dengue virus

Researchers from Johannes Gutenberg University Mainz and the Julius Maximilian University of Würzburg are proposing potential new active substances for treating the dengue virus. Just like Ebola, dengue fever is also caused by a virus for which there is currently no cure and no vaccine and can be fatal.

11 Dec 2014

Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

The drug daclatasvir (trade name Daklinza) has been available since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy.

11 Dec 2014

Study: Simeprevir-based therapy proves effective in treating chronic HCV infection

Researchers at Penn Medicine, in collaboration with a multi-center international team, have shown that a protease inhibitor, simeprevir, a once a day pill, along with interferon and ribavirin has proven as effective in treating chronic Hepatitis C virus infection (HCV) as telaprevir with interferon and ribavirin, the standard of care in developing countries.

10 Dec 2014

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients.

4 Dec 2014

Scientists review HBV-associated tumor microenvironment in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the few cancers in which a continued increase in incidence has been observed over recent years. Globally, there are approximately 750,000 new cases of liver cancer reported each year. Importantly, population-based studies show that HCC ranks as the third leading cause of cancer-related deaths worldwide.

4 Dec 2014

Joint therapy to counter HIV and HCV increases chance of success

A Spanish researcher has collaborated on a mathematical analysis, recently published in the journal 'Science Translational Medicine', which concludes that joint therapy to counter HIV in patients who also have hepatitis C increases the chance of success in the fight against both infections. Between eight and nine million people worldwide simultaneously suffer from AIDS and hepatitis C.

3 Dec 2014

Leading medical experts across the UK call for radical scale up of liver disease treatment

Leading medical experts today [Thursday 27 November] warn that rising numbers of deaths from liver disease - already the UK's third commonest cause of premature death - will be unavoidable without radical improvements in treatment and detection services, and tougher government policies to control the excessive alcohol use and obesity responsible for much of the national burden of liver disease.

27 Nov 2014

Hepatitis C News and Research

Latest Hepatitis C News and Research

EB Pharma licenses tipifarnib from Janssen to study potential new therapy for HDV

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

Study underscores the importance of appropriate testing, support and care for HCV patients

Medical researchers at Saint Louis University bring hope to those in pain and sickness

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

New analysis finds global improvements in life expectancy

LSDF announces $1.2 million in grants to foster advancement of promising health-related technologies

New study highlights importance of generating awareness about HCV testing, support and care

HEPscreen Toolkit seeks to raise awareness on chronic viral hepatitis in Europe

New study eliminates hepatitis C virus as causative factor of mental impairment in HIV patients

New study helps identify public health needs relating to HIV/AIDS, hepatitis C in Massachusetts

Two MinuteClinic walk-in medical clinics open inside CVS/pharmacy stores in Northern Nevada

Smaller blood transfusions during surgeries better for patients with heart disease

Potential new active substances for treating dengue virus

Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

Study: Simeprevir-based therapy proves effective in treating chronic HCV infection

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Scientists review HBV-associated tumor microenvironment in hepatocellular carcinoma

Joint therapy to counter HIV and HCV increases chance of success

Leading medical experts across the UK call for radical scale up of liver disease treatment

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Hepatitis C News and Research

Latest Hepatitis C News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in